Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Pharmacological Treatment with Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction (SAVA-TTR)

NCT06712030 is registered in ClinicalTrials.gov with Puerta de Hierro University Hospital as lead sponsor.

NCT NCT06712030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06712030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Pharmacological Treatment with Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction (SAVA-TTR)
Lead sponsor
Puerta de Hierro University Hospital
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 31, 2025
Completion date
June 30, 2027
Enrollment
114 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin amyloidosis cardiomyopathy (attr-cm)